Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Emily O’Conno
Advertisement
Articles by Emily O’Conno
Advertisement
Latest Updated Articles
- Challenges to the Specialty Business Model
Published: June 17th 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
3
Study Claims Ozempic Lowers Biological Age
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5
